Running Title: Combination of MK-1775 and gemcitabine in pancreatic cancer
Pancreatic ductal adenocarcinoma (PDA) remains one of the least curable cancers, ranking fourth in cancer related deaths in the United States (1) . Worldwide, PDA contributes to more than 230,000 deaths annually (2) . Gemcitabine (GEM), a pyrimidine antimetabolite, is the accepted standard treatment for patients with advanced and metastatic PDA, but the benefit is small (3) . The addition of other chemotherapeutics or monoclonal antibodies or radiation to GEM has not resulted any meaningful improvement in the survival of PDA patients (4) (5) (6) . As the current therapies offer very limited benefit, there is significant unmet medical need to identify novel molecular targets and develop novel therapeutic strategies to treat this devastating disease (7) .
Treatment efficacy of DNA damaging agents is determined not only by the amount of therapy-induced DNA damage but also by the capacity of tumor cells to repair the damaged DNA. Many of the conventional anticancer treatments including antimetabolites, ionizing radiation, alkylating agents, platinum compounds and DNA topoisomerase inhibitors exert their anti-tumor effects by damaging the DNA in tumor cells which leads to apoptosis (8) . However, when cells are treated with DNA damaging agents, multiple checkpoints are activated, including G 1 , intra-S, and G 2 /M, leading to cell cycle arrest, thus providing time for the cell to repair the damage and to evade 6 p53 is a key regulator of the G 1 checkpoint and is one of the most frequently mutated genes in cancer. Since G 1 checkpoint is frequently compromised due to loss-of-function mutation of p53 gene in 50-70% of all cancers, the G 2 /M checkpoint plays a pivotal role in preventing the programmed cell death in p53-deficient tumors (12, 13) . Hence, inhibitors of the G 2 checkpoint can selectively sensitize cancer cells with deficient-p53 to killing by DNA-damaging anti-cancer agents while sparing normal tissue from toxicity.
The G 2 DNA damage checkpoint ensures maintenance of cell viability by delaying progression into mitosis when cells have suffered DNA damage. Wee1 is a cellular protein kinase which inhibits Cdc2 activity, thereby preventing cells from proceeding through mitosis by maintaining G 2 arrest (14) . Wee1 reversibly arrests the cell cycle by inactivating Cdc2 through phosphorylation at Tyr-15 (15) . Disruption of this phosphorylation site abrogates checkpoint-mediated regulation of Cdc2 (16) . Wee1 knockdown with siRNA has been reported to abrogate the G 2 DNA damage checkpoint arrest and to sensitize cancer cells to DNA damaging agents (17) . Wee1 kinase inhibition is expected to potentiate the anti-tumor effect of DNA damaging chemotherapeutics by overcoming the G 2 arrest and thereby promoting checkpoint bypass to facilitate the preferential killing of p53-deficient tumor cells via mitotic catastrophe.
MK-1775 is the first reported Wee1 inhibitor with high potency, selectivity and oral bioavailability in preclinical animal models and is currently being evaluated in several phase I clinical trials (18-21). Given that p53 mutations are common in pancreatic cancer (22) , we sought to investigate efficacy and pharmacodynamic effects of MK-1775 alone and in combination with GEM in pancreatic cancer xenografts with p53-wild type or p53- 
Materials and methods

Animals and establishment of xenografts model. Animal experiments were conducted
following approval and accordance with Animal Care and Use Committee guidelines of Johns Hopkins University. Fresh pancreatic cancer specimens resected from patients at the time of surgery, with informed written patient consent, were implanted subcutaneously (s.c.) into the flanks of 6-week-old female nu/nu athymic mice (Harlan).
The patients had not undergone chemotherapy or radiation therapy before surgery.
Grafted tumors were subsequently transplanted from mouse to mouse and maintained as a live PancXenoBank according to an IRB approved protocol (23) . Tumor-specific mutations of protein-coding genes (exomic sequencing) in these xenografts have been recently reported (24) . Most importantly, these xenografts were not placed in culture and appear to retain most of the genetic features of the original tumor, despite serial passing across several generations of mice (25, 26). Significance was analyzed using unpaired Student's t-test. The differences were considered significant when P-value was < 0.05.
Results and discussion
The principal aim of this study was to investigate the efficacy of MK-1775 as a single agent and in combination with GEM in PDA xenografts and to assess whether the status of the p53 gene had any role in dictating the efficacy of the treatment. We used a xenograft model which is freshly generated from the tumors taken from pancreatic cancer patients and selected nine xenografts (six xenografts with p53-deficient and three xenografts with p53-wild type status) for this study. As shown in Figure 1A , tumors in vehicle-treated animals grew rapidly. Single agent MK-1775 treatment produced greater than 50% inhibition of tumor growth in two xenografts (PANC286 and PANC198).
However, five of nine xenografts treated with GEM and six of nine xenografts treated with GEM plus MK-1775 produced complete tumor growth inhibition and in fact resulted tumor shrinkage compared to control and MK-1775 treated animals (Fig.1A) . These data suggest that single agent MK-1775 is unlikely to be effective in patients with PDA but that the combination of this agent with GEM has a substantial level of activity, and should be prioritized for clinical development.
Overall, none of the xenografts with p53-deficient status in the GEM treatment group produced 50% regression of initial tumor volume (Fig.1A) . However, combination of GEM and MK-1775 resulted in greater than 50% regression of initial tumor volume in four of six xenografts (66.66%) with p53-deficient status (Fig.1A) . The number of tumors that regressed more than 50% of its initial tumor size in each xenograft upon completion of treatment is provided in Table 1 . Tumors with wild type-p53 status did not regress with treatments (Table 1) . Among the xenografts with p53-deficient status, GEM alone treatment induced regression in 7 of 55 tumors (12.72%), while MK-1775 in combination with GEM induced regressions in 25 of 49 tumors (51.10%) in the six xenografts. Tumor growth regressions in GEM plus MK-1775 treated mice were found to be significant in PANC198 (P < 0.0001), PANC215 (P < 0.005) and PANC185 (P < 0.005) as compared to GEM treated mice. There was an overall 4.01 fold increase in total number of tumors regressed in the combination treatment group compared to GEM alone treatment (Fig.1B) . K-ras and SMAD4 status do not influence the tumor regression pattern in the xenografts (Table 1 ). One limitation of preclinical studies is that the threshold of activity that translates into positive clinical outcome is not known. Often, drugs are selected for clinical development base on tumor growth inhibition in preclinical models. As our experience with freshly generated PDA models increases and more comparison data is available, we are observing that indeed only agents that result in marked tumor 
Chk1/2 inhibitors are in clinical development (36-38). A recent report indicated that
Chk1 is required to maintain genome integrity and cell viability, and that p53-wild type cells are no less sensitive than p53-deficient cells to Chk1 inhibition in the presence of DNA damage. Thus, combining Chk1 inhibition with DNA damaging agents does not lead to preferential killing of p53-deficient over p53-wild type cells, and inhibiting Chk1 does not appear to be a promising approach for potentiation of cancer chemotherapy (39) . Here we showed that Wee1 inhibition by MK-1775 could potentiate GEM sensitivity and tumor regressions, selectively in p53-deficient pancreatic cancer xenografts.
We were also interested in long-term tumor growth control and followed three xenografts after treatment for an extended period of time. Tumor re-growth data, as shown in Fig. 2 suggest that not only does the combination of GEM with MK-1775 lead to synergistic tumor growth inhibition, but the effect of the combination therapy is also longer-lasting than that seen with GEM alone (Fig. 2A, B and C) . It was noteworthy, however, that tumors eventually recur, albeit at a slower pace.
In order to determine the target modulation by MK-1775, we examined Wee1, Cdc2 and their phosphorylated forms in post treatment tumor specimens. MK-1775 treatment strongly inhibited phosphorylation of Tyr-15 of Cdc2, the primary substrate of Wee1 (Fig. 3, 4A and C) , suggesting increased Cdc2 kinase activity. In addition, the Wee1 protein was consistently reduced by MK-1775 treatment as shown by western blotting (Fig. 3) , likely due to degradation of Wee1 as MK-1775 treatment activates Cdc2 which in turn phosphorylates Wee1, ultimately leading to its ubiquitin-proteasome dependent destruction (40) .
To determine whether combination therapy promotes mitotic entry, we measured the expression of phospho histone H3 by western blot as well as by immunohistochemistry.
When administered in combination with GEM, MK-1775 promoted mitotic entry as measured by enhanced phospho histone H3 expression (Fig. 3, 4B and D) . In addition, the combined treatment resulted in the up-regulation of C-PARP as well as down regulation of cIAP2, suggesting that combination therapy facilitates apoptotic death of tumor cells (Fig. 3) . GEM, as a chain terminator, requires an active cell cycle to be effective for inhibiting tumor growth, and might induce cell cycle halt and enforce cell cycle checkpoints, which may play an important role in escalating the resistance to therapy. Thus, there is a strong rationale in combining checkpoint inhibitors with GEM as a means to enhance tumor response (41, 42 ). Here we showed that GEM induces G 2 arrest, which correlates with an increased Cdc2 inhibitory phosphorylation at Tyr-15 and prevents mitotic entry as evidenced by decreased p-HH3 Ser10 (Fig 4B and D) . However, Animals were treated with vehicle, MK-1775, GEM or GEM + MK-1775 for 4 weeks.
Tumors that regressed greater than 50% of its size on day 28 in each xenograft were counted. Numbers in parenthesis denotes total number of tumors in that xenograft. Over all, 7of 55 (12.72%) tumors with p53-deficient (MUT) status regressed in the GEM treatment group. However, 25 of 49 (51.10%) of tumors with p53 MUT status regressed in the GEM + MK-1775 group. None of the tumors with p53-wild type (WT) regressed in GEM + MK-1775 (0 of 23) or GEM (0 of 26) treatment groups. K-ras and SMAD4 status do not influence the tumor regression pattern in these xenografts.
